AAPL315.91-4.06 (-1.27%) ▼|ABBV250.62-5.84 (-2.28%) ▼|ABT105.97-2.37 (-2.18%) ▼|ACN177.76-8.96 (-4.80%) ▼|ADBE257.30-9.22 (-3.46%) ▼|AMAT470.11+15.40 (+3.39%) ▲|AMD510.97+33.40 (+6.99%) ▲|AMGN397.35-39.88 (-9.12%) ▼|AMT177.08+1.23 (+0.70%) ▲|AMZN257.01-1.50 (-0.58%) ▼|AVGO367.18+9.29 (+2.59%) ▲|AXP326.95+0.79 (+0.24%) ▲|BA211.52-0.73 (-0.34%) ▼|BAC62.70+0.02 (+0.02%) ▲|BKNG180.60-12.69 (-6.57%) ▼|BLK1,104.39-12.18 (-1.09%) ▼|BMY65.06-1.76 (-2.63%) ▼|BNY164.00-0.84 (-0.51%) ▼|BRK-B504.46-1.58 (-0.31%) ▼|C137.58-0.15 (-0.11%) ▼|CAT826.91+12.97 (+1.59%) ▲|CL88.60-0.17 (-0.19%) ▼|CMCSA26.08-0.41 (-1.55%) ▼|COF215.20-4.40 (-2.00%) ▼|COP134.37+0.11 (+0.08%) ▲|COST909.62-6.13 (-0.67%) ▼|CRM248.81-10.43 (-4.02%) ▼|CSCO109.08-0.12 (-0.11%) ▼|CVS96.49-0.25 (-0.26%) ▼|CVX209.56+0.96 (+0.46%) ▲|DE683.49-10.05 (-1.45%) ▼|DHR206.03-1.63 (-0.78%) ▼|DIS104.56-0.76 (-0.72%) ▼|DUK121.26+1.04 (+0.86%) ▲|EMR152.12-0.70 (-0.46%) ▼|FDX316.67-5.85 (-1.81%) ▼|GD356.85-2.54 (-0.71%) ▼|GE337.88+0.76 (+0.23%) ▲|GEV970.68+28.73 (+3.05%) ▲|GILD146.62-4.38 (-2.90%) ▼|GM86.01-1.76 (-2.00%) ▼|GOOG336.36+1.05 (+0.31%) ▲|GOOGL339.57+1.11 (+0.33%) ▲|GS1,036.86-1.75 (-0.17%) ▼|HD315.43-5.63 (-1.75%) ▼|HON208.35-1.27 (-0.60%) ▼|IBM232.28-2.62 (-1.11%) ▼|INTC105.74+9.94 (+10.38%) ▲|INTU313.48-19.22 (-5.78%) ▼|ISRG351.24-15.46 (-4.22%) ▼|JNJ269.14-6.09 (-2.21%) ▼|JPM355.16-3.49 (-0.97%) ▼|KO88.36+0.29 (+0.32%) ▲|LIN468.57-9.00 (-1.88%) ▼|LLY1,126.65-22.71 (-1.98%) ▼|LMT538.18+12.90 (+2.46%) ▲|LOW201.70-2.76 (-1.35%) ▼|LRCX320.04+12.39 (+4.03%) ▲|MA567.69-11.52 (-1.99%) ▼|MCD255.75+0.06 (+0.02%) ▲|MDLZ61.43+0.15 (+0.24%) ▲|MDT92.59-1.58 (-1.68%) ▼|META617.95+1.18 (+0.19%) ▲|MMM166.52-2.04 (-1.21%) ▼|MO68.04-0.84 (-1.22%) ▼|MRK148.81-1.52 (-1.01%) ▼|MS217.85+0.13 (+0.06%) ▲|MSFT492.30-7.41 (-1.48%) ▼|MU1,018.61+2.02 (+0.20%) ▲|NEE84.04+0.61 (+0.73%) ▲|NFLX76.72-1.53 (-1.96%) ▼|NKE38.17-0.23 (-0.60%) ▼|NOW133.81-7.46 (-5.28%) ▼|NVDA225.90-4.47 (-1.94%) ▼|ORCL162.52+3.74 (+2.35%) ▲|PEP138.27+0.64 (+0.47%) ▲|PFE27.94-0.52 (-1.81%) ▼|PG145.34-1.10 (-0.75%) ▼|PLTR171.94-2.39 (-1.37%) ▼|PM185.54+3.01 (+1.65%) ▲|QCOM174.78+6.04 (+3.58%) ▲|RTX199.49-1.30 (-0.65%) ▼|SBUX102.27-2.20 (-2.11%) ▼|SCHW108.52-0.78 (-0.71%) ▼|SO88.89+0.78 (+0.89%) ▲|SPG211.61+2.17 (+1.04%) ▲|T25.50-0.18 (-0.70%) ▼|TMO605.92-7.86 (-1.28%) ▼|TMUS179.68-1.84 (-1.01%) ▼|TSLA367.79+13.71 (+3.87%) ▲|TXN257.14-1.30 (-0.50%) ▼|UBER73.24-2.52 (-3.33%) ▼|UNH403.34+6.20 (+1.56%) ▲|UNP290.17+0.55 (+0.19%) ▲|UPS100.82-1.48 (-1.44%) ▼|USB62.83-0.55 (-0.86%) ▼|V368.69-6.38 (-1.70%) ▼|VZ50.13-0.02 (-0.03%) ▼|WFC88.83-1.14 (-1.27%) ▼|WMT106.07-1.08 (-1.00%) ▼|XOM159.49+0.02 (+0.01%) ▲|AAPL315.91-4.06 (-1.27%) ▼|ABBV250.62-5.84 (-2.28%) ▼|ABT105.97-2.37 (-2.18%) ▼|ACN177.76-8.96 (-4.80%) ▼|ADBE257.30-9.22 (-3.46%) ▼|AMAT470.11+15.40 (+3.39%) ▲|AMD510.97+33.40 (+6.99%) ▲|AMGN397.35-39.88 (-9.12%) ▼|AMT177.08+1.23 (+0.70%) ▲|AMZN257.01-1.50 (-0.58%) ▼|AVGO367.18+9.29 (+2.59%) ▲|AXP326.95+0.79 (+0.24%) ▲|BA211.52-0.73 (-0.34%) ▼|BAC62.70+0.02 (+0.02%) ▲|BKNG180.60-12.69 (-6.57%) ▼|BLK1,104.39-12.18 (-1.09%) ▼|BMY65.06-1.76 (-2.63%) ▼|BNY164.00-0.84 (-0.51%) ▼|BRK-B504.46-1.58 (-0.31%) ▼|C137.58-0.15 (-0.11%) ▼|CAT826.91+12.97 (+1.59%) ▲|CL88.60-0.17 (-0.19%) ▼|CMCSA26.08-0.41 (-1.55%) ▼|COF215.20-4.40 (-2.00%) ▼|COP134.37+0.11 (+0.08%) ▲|COST909.62-6.13 (-0.67%) ▼|CRM248.81-10.43 (-4.02%) ▼|CSCO109.08-0.12 (-0.11%) ▼|CVS96.49-0.25 (-0.26%) ▼|CVX209.56+0.96 (+0.46%) ▲|DE683.49-10.05 (-1.45%) ▼|DHR206.03-1.63 (-0.78%) ▼|DIS104.56-0.76 (-0.72%) ▼|DUK121.26+1.04 (+0.86%) ▲|EMR152.12-0.70 (-0.46%) ▼|FDX316.67-5.85 (-1.81%) ▼|GD356.85-2.54 (-0.71%) ▼|GE337.88+0.76 (+0.23%) ▲|GEV970.68+28.73 (+3.05%) ▲|GILD146.62-4.38 (-2.90%) ▼|GM86.01-1.76 (-2.00%) ▼|GOOG336.36+1.05 (+0.31%) ▲|GOOGL339.57+1.11 (+0.33%) ▲|GS1,036.86-1.75 (-0.17%) ▼|HD315.43-5.63 (-1.75%) ▼|HON208.35-1.27 (-0.60%) ▼|IBM232.28-2.62 (-1.11%) ▼|INTC105.74+9.94 (+10.38%) ▲|INTU313.48-19.22 (-5.78%) ▼|ISRG351.24-15.46 (-4.22%) ▼|JNJ269.14-6.09 (-2.21%) ▼|JPM355.16-3.49 (-0.97%) ▼|KO88.36+0.29 (+0.32%) ▲|LIN468.57-9.00 (-1.88%) ▼|LLY1,126.65-22.71 (-1.98%) ▼|LMT538.18+12.90 (+2.46%) ▲|LOW201.70-2.76 (-1.35%) ▼|LRCX320.04+12.39 (+4.03%) ▲|MA567.69-11.52 (-1.99%) ▼|MCD255.75+0.06 (+0.02%) ▲|MDLZ61.43+0.15 (+0.24%) ▲|MDT92.59-1.58 (-1.68%) ▼|META617.95+1.18 (+0.19%) ▲|MMM166.52-2.04 (-1.21%) ▼|MO68.04-0.84 (-1.22%) ▼|MRK148.81-1.52 (-1.01%) ▼|MS217.85+0.13 (+0.06%) ▲|MSFT492.30-7.41 (-1.48%) ▼|MU1,018.61+2.02 (+0.20%) ▲|NEE84.04+0.61 (+0.73%) ▲|NFLX76.72-1.53 (-1.96%) ▼|NKE38.17-0.23 (-0.60%) ▼|NOW133.81-7.46 (-5.28%) ▼|NVDA225.90-4.47 (-1.94%) ▼|ORCL162.52+3.74 (+2.35%) ▲|PEP138.27+0.64 (+0.47%) ▲|PFE27.94-0.52 (-1.81%) ▼|PG145.34-1.10 (-0.75%) ▼|PLTR171.94-2.39 (-1.37%) ▼|PM185.54+3.01 (+1.65%) ▲|QCOM174.78+6.04 (+3.58%) ▲|RTX199.49-1.30 (-0.65%) ▼|SBUX102.27-2.20 (-2.11%) ▼|SCHW108.52-0.78 (-0.71%) ▼|SO88.89+0.78 (+0.89%) ▲|SPG211.61+2.17 (+1.04%) ▲|T25.50-0.18 (-0.70%) ▼|TMO605.92-7.86 (-1.28%) ▼|TMUS179.68-1.84 (-1.01%) ▼|TSLA367.79+13.71 (+3.87%) ▲|TXN257.14-1.30 (-0.50%) ▼|UBER73.24-2.52 (-3.33%) ▼|UNH403.34+6.20 (+1.56%) ▲|UNP290.17+0.55 (+0.19%) ▲|UPS100.82-1.48 (-1.44%) ▼|USB62.83-0.55 (-0.86%) ▼|V368.69-6.38 (-1.70%) ▼|VZ50.13-0.02 (-0.03%) ▼|WFC88.83-1.14 (-1.27%) ▼|WMT106.07-1.08 (-1.00%) ▼|XOM159.49+0.02 (+0.01%) ▲|
25.3 C
New York
Tuesday, September 8, 2026

Tag: 7

newssourceFORcompanyinformationcontent1releasesmarket

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

Injectable Offers Potential to Reduce Fatty Liver Diseases and Improve Health Markers in AdultsNEW ORLEANS, June 7, 2026 /PRNewswire/ -- New data highlight the potential...

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 7, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6

Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist

Copenhagen, Denmark, 7 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today presented key Phase 1 and preclinical data for AT7687 at the 2026 Scientific Sessions of the American Diabetes Association®, held in New Orleans, Louisiana from June 5-8, 2026.

CREDIT AGRICOLE S.A. ANNOUNCES REDEMPTION OF ¥84,200,000,000 Japanese Yen Callable Senior Non-Preferred Bonds issued on June 3, 2021 (ISIN: JP525022AM69)

Montrouge, June 8, 2026

CREDIT AGRICOLE S.A. ANNONCE LE REMBOURSEMENT DE SES Obligations senior non préférées remboursables émises le 3 juin 2021 pour un montant nominal total de...

CREDIT AGRICOLE S.A. ANNONCE LE REMBOURSEMENT DE SES

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Immutep (IMMP) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 7/6/2026

Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, June 7, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit...

Bronstein, Gewirtz & Grossman LLC Urges Badger Meter, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, June 7, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit...

Bronstein, Gewirtz & Grossman LLC Urges CommVault Systems, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for CommVault (CVLT) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 7/17/2026

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage...

In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTags7

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers